Antitumor protein hybrid and process for the preparation thereof
AssigneesTeijin Limited, Hidematsu Hirai
InventorsYasuhiko Masuho, Naoji Umemoto, Takeshi Hara, Hidematsu Hirai
Life of this patent
Estimating the term…
Loading patent…
AssigneesTeijin Limited, Hidematsu Hirai
InventorsYasuhiko Masuho, Naoji Umemoto, Takeshi Hara, Hidematsu Hirai
Estimating the term…
Antitumor protein hybrid, having a moiety consisting of the antitumor immunoglobulin and a moiety substantially consisting of the fragment A of a diphtheria toxin, which is expressed by the following formula (I): Ab(NHCO--X--S.sub.1 --S.sub.2 --FA).sub.n (I) (where Ab indicates a moiety consisting of the antitumor immunoglobulin and FA indicates a moiety substantially consisting of the fragment A of a diphtheria toxin; X is an alkylene group or phenylene group which either has or does not have a branching of 1 to 5 carbon atoms. N in the amido bond is a nitrogen atom arising from the amino group in the antitumor immunoglobulin; S.sub.1 and S.sub.2 are both sulfur atoms, S.sub.2 indicating a sulfur atom arising from the disulfide bond in a diphtheria toxin; n stands for an integer of 1 to 5). This antitumor protein hybrid has remarkable and specific citotoxicity against tumor cells.
Antitumor protein hybrid, having a moiety consisting of the antitumor immunoglobulin and a moiety substantially consisting of the fragment A of a diphtheria toxin, which is expressed by the following formula (I):
Dependencies are inferred from the claim text.